Cardiomyopathy, Dilated

Dilated cardiomyopathy has multiple causes, including genetic variants, epigenetic disorders, infectious insults, autoimmune diseases, and cardiac conduction abnormalities. Familial disease is often genetic, with many identified gene mutations contributing to clinically significant cardiomyopathy, and LMNA mutations are specifically noted among risk-associated variants.

The disease is characterized by chamber dilation and impaired ventricular contraction, leading to reduced cardiac function and heart failure. The literature also links specific genetic defects to altered cardiomyocyte functions, especially abnormalities in cell-cell junctions and the cytoskeleton, and describes immune-cell mediated inflammatory responses after injury as part of the disease process.

Reported risk factors include smoking, alcohol drinking, hypertension, infection, pregnancy, and mutations in the LMNA gene. Genetic predisposition is important, with a substantial fraction of familial cases having an identifiable genetic cause.

Management is described at the level of therapy and precision medicine rather than specific regimens. The literature emphasizes genetic evaluation, cardiac imaging, and precision medicine approaches for genetically defined disease, and notes that dilated cardiomyopathy is a major indication for heart transplantation in severe cases.